tradingkey.logo

Tivic Health Systems Inc

TIVC
2.310USD
-0.060-2.53%
Close 11/04, 16:00ETQuotes delayed by 15 min
2.23MMarket Cap
LossP/E TTM

Tivic Health Systems Inc

2.310
-0.060-2.53%

More Details of Tivic Health Systems Inc Company

Tivic Health Systems, Inc. is a commercial health tech company advancing the field of bioelectronic medicine. The Company’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Its non-invasive and targeted approach to the treatment of inflammatory chronic health conditions is intended to give consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. The Company’s commercial product, ClearUP, is an FDA approved handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and available through online retailers and commercial distributors. ClearUP is sold in the United States directly to consumers on various platforms and through reseller channels. The Company is also focused on its intellectual property (IP) portfolio and research programs related to vagus nerve stimulation to expand its applications in non-invasive bioelectronic medicine.

Tivic Health Systems Inc Info

Ticker SymbolTIVC
Company nameTivic Health Systems Inc
IPO dateNov 11, 2021
CEOMs. Jennifer Ernst
Number of employees7
Security typeOrdinary Share
Fiscal year-endNov 11
Address47685 Lakeview Blvd
CityFREMONT
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94538
Phone18882766888
Websitehttps://tivichealth.com/
Ticker SymbolTIVC
IPO dateNov 11, 2021
CEOMs. Jennifer Ernst

Company Executives of Tivic Health Systems Inc

Name
Name/Position
Position
Shareholding
Change
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
23.25K
+3192.78%
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
23.25K
+3192.78%
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--

Revenue Breakdown

No Data
No Data
By Business
By Region
No Data

Shareholding Stats

Updated: Thu, Oct 2
Updated: Thu, Oct 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Statera BioPharma, Inc
3.89%
Avenue Venture Opportunities Fund LP
3.18%
Marex Group plc
2.50%
Ernst (Jennifer)
1.48%
UBS Financial Services, Inc.
0.36%
Other
88.60%
Shareholders
Shareholders
Proportion
Statera BioPharma, Inc
3.89%
Avenue Venture Opportunities Fund LP
3.18%
Marex Group plc
2.50%
Ernst (Jennifer)
1.48%
UBS Financial Services, Inc.
0.36%
Other
88.60%
Shareholder Types
Shareholders
Proportion
Corporation
7.07%
Investment Advisor
2.85%
Individual Investor
1.51%
Other
88.56%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
2023Q3
33
160.42K
18.20%
+130.18K
2023Q2
33
60.32K
19.16%
+13.93K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Statera BioPharma, Inc
61.20K
3.89%
+61.20K
--
May 14, 2025
Avenue Venture Opportunities Fund LP
50.13K
3.18%
+50.13K
--
May 14, 2025
Marex Group plc
39.28K
2.5%
+39.28K
--
Jun 30, 2025
Ernst (Jennifer)
23.25K
1.48%
+22.54K
+3192.78%
Sep 22, 2025
UBS Financial Services, Inc.
5.65K
0.36%
+5.65K
--
Jun 30, 2025
Bambach (Kimberly Ann)
442.00
0.03%
--
--
May 14, 2025
Gurfein (Blake Ph.D.)
66.00
0%
--
--
May 14, 2025
SBI Securities Co., Ltd.
16.00
0%
--
--
Jun 30, 2025
BofA Global Research (US)
9.00
0%
+4.00
+80.00%
Jun 30, 2025
Susquehanna International Group, LLP
--
0%
-927.00
-100.00%
Dec 31, 2024
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Date
Type
Ratio
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
KeyAI